Actelion Pharmaceuticals settlements

Actelion Pharmaceuticals is the subject of a $65 million class action settlement involving alleged anticompetitive conduct related to its drugs Tracleer and bosentan. This settlement is specifically limited to third-party payors — such as health insurers, HMOs, and self-insured plans — that purchased, paid for, or reimbursed Tracleer or bosentan for members between December 29, 2015 and September 6, 2024. Individual consumers are not included in this settlement class. Eligible payors must submit documentation and file through the official claim form by August 3, 2026.

Check what you may be owed Free · takes 20 seconds

Published directory

1 published record

Proof required

Antitrust

Actelion Pharmaceuticals $65M Tracleer, Bosentan Settlement

Actelion Pharmaceuticals agreed to pay $65 million to resolve claims that it blocked generic competition for the drug Tracleer (bosentan). The deal covered health insurers and other third-party payors that bought or reimbursed the drug from December 29, 2015 through September 6, 2024, not individual patients. The claim filing window has closed.

Set at final approval

Potential payment

Closed

Aug 3, 2026

Claim window closed Official evidence on file

Related companies with published settlements

Share this collection — free to repost with a link back.

There may be money with your name on it.

Free to browse and track. Every record shows its official-evidence status — and you open the official claim form yourself.

Check what you may be owed Browse all settlements